Press release
Advancing Pharmaceutical Analysis with Bedaquiline Impurity Standards: Aquigen Bio's Comprehensive Portfolio
In the dynamic landscape of pharmaceutical development, impurity profiling plays a pivotal role in ensuring drug safety, efficacy, and regulatory compliance. With rising regulatory scrutiny and evolving analytical methodologies, the need for high-purity impurity standards has never been greater-especially for critical anti-tuberculosis drugs like Bedaquiline.At Aquigen Bio, our dedication to analytical integrity and pharmaceutical innovation has led to the development of a comprehensive suite of Bedaquiline impurity standards. These compounds are tailored to meet the needs of quality control labs, formulation scientists, and regulatory experts involved in the development, validation, and manufacturing of Bedaquiline-based formulations.
In this blog, we'll explore the importance of Bedaquiline impurity standards, the challenges associated with impurity identification, and how Aquigen Bio's specialized reference materials-like Bedaquiline Impurity 6 and Bedaquiline D6-are facilitating progress across the pharmaceutical industry.
Understanding Bedaquiline: A Breakthrough in TB Therapy
Bedaquiline is a diarylquinoline antimycobacterial drug primarily used for the treatment of multidrug-resistant tuberculosis (MDR-TB). Approved by the USFDA and WHO, it represents a significant leap in global TB management due to its unique mechanism-targeting ATP synthase in Mycobacterium tuberculosis.
However, like any API (Active Pharmaceutical Ingredient), the manufacturing and degradation pathways of Bedaquiline can lead to the formation of impurities. These impurities-whether process-related, degradation products, or synthetic byproducts-must be identified, quantified, and controlled within acceptable regulatory limits.
Why Bedaquiline Impurity Standards Are Crucial
Impurities in pharmaceutical substances may compromise drug safety and therapeutic performance. Global regulatory bodies like the ICH, USFDA, and EMA mandate thorough impurity profiling for both new and generic drug applications.
For Bedaquiline, specific impurities must be monitored at trace levels due to potential safety concerns, including genotoxicity or reduced efficacy. This is where certified impurity standards come into play-they are essential for:
Analytical method development and validation
Impurity quantification and threshold identification
Stability testing under various stress conditions
Regulatory filings (ANDA, DMF, etc.)
Aquigen Bio provides a diverse collection of Bedaquiline impurity standards that empower laboratories to meet these stringent requirements with confidence.
Aquigen Bio's Bedaquiline Impurity Portfolio
We offer an expanding range of impurity reference materials designed specifically for Bedaquiline-related analysis. Each compound is synthesized under strict quality controls and is supplied with a comprehensive Certificate of Analysis (CoA), including NMR, MS, and HPLC purity data.
Let's explore some of our most in-demand Bedaquiline impurities:
1. Bedaquiline Impurity 6
https://aquigenbio.com/product/bedaquiline-impurity-6/
Bedaquiline Impurity 6 is a vital analytical standard used for routine monitoring of side-products in the Bedaquiline synthesis process. It is highly useful during:
Stress testing of formulations
Identification of synthetic route deviations
Evaluation of impurity fate during shelf-life studies
This impurity is isolated and characterized with a purity level exceeding 98%, ensuring consistent analytical performance across laboratories.
2. Bedaquiline D6
https://aquigenbio.com/product/bedaquiline-d6/
The Bedaquiline D6 compound is a deuterated internal standard used extensively in LC-MS/MS applications. By replacing hydrogen atoms with deuterium, Bedaquiline D6 provides:
Enhanced signal clarity
Better detection limits for Bedaquiline quantification
Greater reproducibility in bioanalytical assays
Pharmacokinetic and bioequivalence studies particularly benefit from the use of this stable isotope-labeled standard, making it indispensable for clinical research organizations and pharmaceutical sponsors alike.
3. Bedaquiline Nitroso Impurity 2
https://aquigenbio.com/product/bedaquiline-nitroso-impurity-2/
Nitrosamine impurities are under intense scrutiny globally due to their potential genotoxic and carcinogenic properties. Bedaquiline Nitroso Impurity 2 is developed specifically to assist in:
Nitrosamine risk assessment
Quantification under ICH M7 guidelines
LC-MS method validation at ppb (parts per billion) levels
With the increasing regulatory focus on nitrosamines, this impurity standard is vital for ensuring compliance and patient safety.
4. Bedaquiline Des-Bromo Diastereomer Impurity 1
https://aquigenbio.com/product/bedaquiline-des-bromo-diastereomer-impurity-1/
This impurity arises due to minor alterations in stereochemistry and halogen substitution during synthesis. It helps in:
Identifying chiral purity deviations
Supporting stereoselective synthesis validations
Providing reference for stability-indicating method development
Diastereomeric impurities are often difficult to detect without highly specific reference standards, making Aquigen Bio's offering invaluable for comprehensive Bedaquiline analysis.
Use Cases: Who Needs These Impurity Standards?
Aquigen Bio's Bedaquiline impurity standards are ideal for:
Generic manufacturers filing ANDAs or DMFs
CROs and CDMOs conducting method validation
QC labs performing routine impurity analysis
Regulatory bodies involved in dossier evaluation
Academic researchers in analytical chemistry and pharmacology
With global shipping and rapid delivery, Aquigen Bio ensures that critical reference materials reach your lab on time, wherever you are in the world.
Aquigen Bio Sciences
281/1, Plot No 41,
Hinjawadi - Pirangut Rd,
Kasar Amboli, Pirangut,
Pune, Maharashtra 412108
Visit: www.aquigenbio.com
Aquigen Bio Sciences stands as India's premier resource for high-quality N-Nitroso impurity standards, impelling advancements in pharmaceutical research and manufacturing. Specializing in providing precise impurity standards - including degradation impurities, process impurities, and deuterated isotopes - Aquigen Bio Sciences empowers the industry to comply with the most rigorous global regulations. The contract research organization's commitment to precision and reliability makes it the trusted partner for addressing complex issues like N-Nitroso impurities in pharmaceuticals.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advancing Pharmaceutical Analysis with Bedaquiline Impurity Standards: Aquigen Bio's Comprehensive Portfolio here
News-ID: 4076835 • Views: …
More Releases from Aquigen Bio Sciences

Estradiol Valerate EP Impurity A - Premium Reference Standard for Analytical Dev …
Estradiol Valerate EP Impurity A is a high-quality reference standard designed to meet the stringent requirements of pharmaceutical research, method validation, and quality control processes.
Explore Estradiol Valerate EP Impurity A :
https://aquigenbio.com/product/estradiol-valerate-ep-impurity-a/
Manufactured and characterized with precision, this impurity standard supports laboratories and manufacturers in achieving consistent, reliable, and reproducible results in critical analytical workflows.
With its exceptional purity and accurate characterization, Estradiol Valerate EP Impurity A plays a vital role…

High-Purity N-Nitroso Betahistine D3 for Precise Pharmaceutical Analysis | Deute …
Product Overview
N-Nitroso Betahistine D3 is a premium deuterated nitrosamine impurity standard, specifically developed for precise analytical testing in pharmaceutical laboratories. This reference standard is widely used for analytical method development, validation, and quality control processes to meet stringent regulatory guidelines. With exceptional purity, complete documentation, and reliable traceability, it is ideal for research, development, and compliance applications.
https://aquigenbio.com/product/n-nitroso-betahistine-d3/
Key Features and Benefits
Deuterated Design for Precision: The incorporation of deuterium improves mass spectrometric…

Aquigen Bio Strengthens Pharmaceutical Research with High-Purity Icatibant Impur …
Aquigen Bio, a trusted supplier of pharmaceutical reference standards, today announced the expansion of its Icatibant Impurity Standards portfolio, designed to support drug developers, analytical laboratories, and research organizations with reliable materials for impurity profiling and quality control.
Icatibant, a selective bradykinin B2 receptor antagonist, is widely used in the treatment of hereditary angioedema (HAE). Given its peptide-based structure, Icatibant is prone to the formation of impurities during synthesis and storage.…

Elevating Analytical Precision with Harmine Impurity Standards
In the realm of pharmaceutical research, controlling the purity of compounds is pivotal. When evaluating psychoactive alkaloids such as harmine-a β-carboline alkaloid known for its reversible monoamine oxidase A inhibition and emerging therapeutic potential-accuracy is non-negotiable. This is where Aquigen Bio Sciences brings its edge: supplying high-grade impurity standards to underpin analytical consistency and regulatory compliance.
Why Harmine Impurity Standards Matter
https://aquigenbio.com/products/impurity-standards/harmine/
Harmine occurs naturally in Peganum harmala and Banisteriopsis caapi, and has…
More Releases for Bedaquiline
Nontuberculous Mycobacterial Infections Pipeline Outlook 2025 - Clinical Trials, …
DelveInsight's report, "Nontuberculous Mycobacterial Infections Pipeline Insight, 2025", provides a detailed overview of the current clinical landscape and future opportunities within the NTM Infections market.
According to DelveInsight's evaluation, the global Nontuberculous Mycobacterial (NTM) Infections pipeline includes 10+ leading companies actively engaged in advancing more than 10 therapeutic candidates. The analysis highlights ongoing progress in clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and developmental milestones.
Request for sample page…
Revolutionizing the Fight Against Tuberculosis: Global Anti-Tuberculosis Therape …
The global Anti-Tuberculosis (TB) Therapeutics Market is on the cusp of a transformative era, driven by urgent medical need, groundbreaking scientific advances, and expanding public-private partnerships. With an estimated 10 million new TB cases reported worldwide in 2022 and 1.4 million deaths, tuberculosis remains a leading infectious disease killer, commanding critical attention from healthcare providers, governments, and pharmaceutical innovators alike. As the world rallies to eliminate this centuries-old scourge, the…
Nontuberculous Mycobacterial Infections Pipeline 2025: Therapies Under Investiga …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Nontuberculous Mycobacterial Infections pipeline constitutes 10+ key companies continuously working towards developing 10+ Nontuberculous Mycobacterial Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Nontuberculous Mycobacterial Infections Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Nontuberculous Mycobacterial…
Tuberculosis Treatment Market Size, Share, Industry Growth 2032
Global Tuberculosis Treatment Market Overview
The global tuberculosis (TB) treatment market is poised for significant growth due to the increasing incidence of TB and favorable government initiatives to combat the disease. Tuberculosis remains a leading global health challenge, with millions affected annually, particularly in developing nations. In response, governments worldwide are implementing policies to improve TB diagnostics, treatment availability, and affordability. The rise of drug-resistant tuberculosis (DR-TB) further underscores the need…
Empowering Growth: Bedaquiline Fumarate Medications Market 2024 and Industry Seg …
The latest research study released by Worldwide Market Reports on "Bedaquiline Fumarate Medications Market 2024 Forecast to 2031" research provides accurate economic, global, and country-level predictions and analyses. It provides a comprehensive perspective of the competitive market as well as an in-depth supply chain analysis to assist businesses in identifying major changes in industry practices. The market report also examines the current state of the Bedaquiline Fumarate Medications industry, as…
In-Depth Insights in Bedaquiline Fumarate Medications Market Research 2023-2030 …
The Bedaquiline Fumarate Medications Market, where demand is steadily increasing due to improved purchasing power, is expected to be beneficial for the global market. This comprehensive research report is an exhaustive compilation of market developments and growth factors optimizing their future growth trajectories from accurate data on the products, strategies, and market shares of the leading players in this particular market. Our latest publication, titled "Bedaquiline Fumarate Medications Market Research…